The Use of Burosumab to Treat Autosomal-recessive Hypophosphatemic Rickets Type 2: Rationale and a First Clinical Experience
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Rutsch F, Salusky I, Ferreira C J Nephrol. 2024; 37(8):2059-2060.
PMID: 39162952 PMC: 11649749. DOI: 10.1007/s40620-024-02057-9.
References
1.
Thacher T, Fischer P, Pettifor J, Lawson J, Manaster B, Reading J
. Radiographic scoring method for the assessment of the severity of nutritional rickets. J Trop Pediatr. 2000; 46(3):132-9.
DOI: 10.1093/tropej/46.3.132.
View
2.
Kung C, Haykir B, Schnitzbauer U, Egli-Spichtig D, Hernando N, Wagner C
. Fibroblast growth factor 23 leads to endolysosomal routing of the renal phosphate cotransporters NaPi-IIa and NaPi-IIc in vivo. Am J Physiol Renal Physiol. 2021; 321(6):F785-F798.
DOI: 10.1152/ajprenal.00250.2021.
View
3.
Hoppner J, Kornak U, Sinningen K, Rutsch F, Oheim R, Grasemann C
. Autosomal recessive hypophosphatemic rickets type 2 (ARHR2) due to ENPP1-deficiency. Bone. 2021; 153:116111.
DOI: 10.1016/j.bone.2021.116111.
View
4.
Carpenter T, Whyte M, Imel E, Boot A, Hogler W, Linglart A
. Burosumab Therapy in Children with X-Linked Hypophosphatemia. N Engl J Med. 2018; 378(21):1987-1998.
DOI: 10.1056/NEJMoa1714641.
View
5.
Boyce A, Gafni R, Ferreira C
. Generalized Arterial Calcification of Infancy: New Insights, Controversies, and Approach to Management. Curr Osteoporos Rep. 2020; 18(3):232-241.
PMC: 9506683.
DOI: 10.1007/s11914-020-00577-4.
View